Clinical Trial Update: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 imaging trial evaluating ABT 555 in relapsing forms of multiple sclerosis using [11C]-PBR28 PET has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ABT 555

Snippet

Sponsor: AbbVie | Conditions: Multiple Sclerosis | Phase 1 | Status: TERMINATED